Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil-Reference-Cited by-同舟云学术

Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil

Published:2020-06 Issue:3 Volume:44 Page:329-339
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Aguiar Bruna Forte,Campos Guilherme Rodrigues Fernandes,Rodrigues João Paulo Vilela,Marques Nayara Nathie,Molina Bárbara Floriano,Bittar Cintia,Souza Fernanda Fernandes,Martinelli Ana de Lourdes Candolo,Rahal Paula,Pereira Leonardo Régis Leira

Funder

FAPESP

CAPES

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference49 articles.

1. Global hepatitis report,2017

2. Brasil,2018

3. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents;Poordad;J Viral Hepat,2012

4. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor;Harper;ACS medicinal chemistry letters,2012

5. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor;Rosenquist;J Med Chem,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review on the Evolution of Natural Mutation-dependent Antiviral Drug Resistance in Hepatitis C Virus (HCV) Genotypes Prevalent in Saudi Arabia: A Genomic and Therapeutic Perspective;The Natural Products Journal;2024-04-03

2. Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections;Diagnostics;2023-09-30

3. Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir;Biochemistry and Biophysics Reports;2022-07

4. Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals;International Journal of Infectious Diseases;2022-02

5. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis;Revista do Instituto de Medicina Tropical de São Paulo;2022